stockrowNyxoah SA
NYXHNyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024.
- Revenue
- +386.8%
- EPS
- +72.5%
- Free cash flow
- −6.84%
- Total debt
- +173.3%
Quarter to September 2026, against a year earlier
Follow NYXH
Alert me
Nyxoah SA (NYXH) Return on invested capital
Nyxoah SA's return on invested capital over the twelve months to 30 September 2026 was −118.6%, up 4.4 percentage points from fiscal 2025 (−123.0%). Over the past ten years it has ranged from −123.0% (fiscal 2025) to 0.00% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of −7.11% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −123.0% | (48.34) |
| FY2024 | −74.7% | (20.57) |
| FY2023 | −54.1% | 1.37 |
| FY2022 | −55.5% | 12.31 |
| FY2021 | −67.8% | (23.80) |
| FY2020 | −44.0% | (43.96) |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ZOMDF Zomedica Corp. compare | −17.1% |
| MXCT MaxCyte, Inc. compare | −42.4% |
| OM Outset Medical, Inc. compare | −84.7% |
| CATX Perspective Therapeutics, Inc. compare | −87.1% |
| NYXH Nyxoah SA | −118.6% |
| SERA Sera Prognostics, Inc. compare | −278.6% |
| HYPR Hyperfine, Inc. compare | −309.8% |
| MBOT Microbot Medical Inc. compare | −850.5% |
| LUCD Lucid Diagnostics Inc. compare | −3,096.5% |
| Medical Devices industry median | −7.11% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)